Rezolute, Inc.
$3.37
▼
-0.32%
2026-04-21 09:16:01
www.rezolutebio.com
NCM: RZLT
Explore Rezolute, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$322.5 M
Current Price
$3.37
52W High / Low
$11.46 / $1.07
Stock P/E
—
Book Value
$1.23
Dividend Yield
—
ROCE
-48.84%
ROE
-74.02%
Face Value
—
EPS
$-0.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
75
Beta
0.66
Debt / Equity
1
Current Ratio
14.18
Quick Ratio
14.37
Forward P/E
-5.32
Price / Sales
—
Enterprise Value
$216.69 M
EV / EBITDA
-2.45
EV / Revenue
—
Rating
Buy
Target Price
$5.12
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Biohaven Ltd. | $10.82 | — | $1.65 B | — | -222.16% | -3.11% | $24.06 / $7.48 | $0.39 |
| 2. | Ionis Pharmaceuticals, Inc. | $74.84 | — | $12.38 B | — | -13.92% | -70.8% | $86.74 / $27.9 | $3 |
| 3. | OKYO Pharma Limited | $1.59 | — | $85.27 M | — | 127.79% | 82.36% | $3.35 / $1.11 | $-0.09 |
| 4. | Immunovant, Inc. | $28.53 | — | $5.81 B | — | -61.93% | -69.35% | $29.48 / $13.36 | $4.85 |
| 5. | MoonLake Immunotherapeutics | $17.89 | — | $1.32 B | — | -64.61% | -60.78% | $62.75 / $5.95 | $4.27 |
| 6. | Tango Therapeutics, Inc. | $26.39 | — | $3.8 B | — | -29.52% | -37.23% | $26.81 / $1.03 | $2.55 |
| 7. | Quince Therapeutics, Inc. | $1.27 | — | $22.33 M | — | -33.74% | -2.48% | $45.5 / $0.8 | $0.02 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -24.22 M | -19.82 M | -25.85 M | -20.02 M | -17.08 M | — |
| Net Profit | -22.77 M | -18.15 M | -24.39 M | -18.91 M | -15.73 M | — |
| EPS in Rs | -0.24 | -0.19 | -0.25 | -0.2 | -0.16 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -79.89 M | -70.42 M | -55.99 M | -41.61 M |
| Net Profit | -74.41 M | -68.46 M | -51.79 M | -41.06 M |
| EPS in Rs | -0.78 | -0.72 | -0.54 | -0.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 175.49 M | 132.74 M | 123.72 M | 152.42 M |
| Total Liabilities | 13.36 M | 11.73 M | 7.55 M | 2.95 M |
| Equity | 162.13 M | 121 M | 116.17 M | 149.47 M |
| Current Assets | 171.15 M | 128.65 M | 104.91 M | 152.1 M |
| Current Liabilities | 11.91 M | 9.61 M | 5.2 M | 2.46 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -69.08 M | -57.37 M | -44.48 M | -39.62 M |
| Investing CF | -14.54 M | 48.7 M | -101.46 M | 0 M |
| Financing CF | 107.33 M | 63.03 M | 11.57 M | 148.98 M |
| Free CF | -69.08 M | -57.37 M | -44.63 M | -39.62 M |
| Capex | — | — | -0.15 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -32.19% | -26.13% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.